Fairview Specialty Pharmacy will now be distributing Symdeko™ (tezacaftor/ivacaftor and ivacaftor), which is approved for treatment of cystic fibrosis.
The FDA approved Symdeko on Feb. 12, 2018. Symdeko is a prescription medicine used to treat patients aged 12 years and older who have two copies of the F508del mutation, or who have at least one mutation in the cystic fibrosis gene that is responsive to treatment with Symdeko.
“We are excited to bring this innovative treatment to those living with cystic fibrosis, supported by our market-leading customer experience and expert clinical care,” said Kari Amundson, vice president of specialty development, Fairview Specialty Pharmacy. “Being part of the Symdeko limited distribution network enables us to provide comprehensive care to patients who receive treatment at the Minnesota Cystic Fibrosis Center, as well as cystic fibrosis centers we serve across the United States.”
Cystic fibrosis is a rare, progressive, life-shortening genetic disease that causes a buildup of mucus, which can lead to persistent lung infections and limits the ability to breathe over time.
“Fairview Specialty Pharmacy’s experience working closely with clinicians in the treatment of cystic fibrosis at the Minnesota Cystic Fibrosis Center puts us in a unique position to support patients who are prescribed Symdeko,” Amundson said. “We tap into this insight to provide individualized care, engage patients in their therapy and help them receive the most value from their medications.”
Fairview Specialty Pharmacy offers individualized care and expert clinical support from experienced staff who are passionate about delivering exemplary service. Because every customer interaction is important, all calls are answered live. Industry-leading customer satisfaction scores attest to Fairview’s ability to get specialty drugs to people who need them, when they need them.